This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cole, P. D. Articles by Kamen, B. A. Search for Related Content PubMed PubMed Citation Articles by Cole, P. D. Articles by Kamen, B. A.

Phase II Trial of Oral Aminopterin for Adults and Children with Refractory Acute Leukemia

Authors' Affiliations: ¹ Department of Pediatric Oncology, The Cancer Institute of New Jersey; and ² Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey; ³ The University of Chicago, Chicago, Illinois; ⁴ Children's Hospital and Regional Medical Center, Seattle, Washington; and ⁵ Columbia University, New York, New York

Requests for reprints: Peter D. Cole, Department of Pediatric Hematology/Oncology, The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901. Phone: 732-235-8076; Fax: 732-235-6462; E-mail: colepd{at}umdnj.edu.

Purpose: To determine the antileukemic activity of weekly oral aminopterin in patients with refractory acute leukemia; to describe the pharmacodynamic properties of aminopterin; and to contrast the intracellular metabolism of aminopterin and methotrexate by patients' blasts in vitro.

Experimental Design: Forty-six patients were enrolled in three strata: children with acute lymphoblastic leukemia (ALL), adults with ALL, and patients with acute myeloid leukemia (AML). Aminopterin was given weekly, in two doses of 2 mg/m², 12 hours apart. Limited sampling pharmacokinetic analysis was done during the first week of therapy. Accumulation of [³H]aminopterin and [³H]methotrexate by leukemic blasts was studied in vitro.

Results: Six of 22 children with ALL (27%; 95% confidence interval, 8-47%) had clinically significant responses. None of those with AML and only two of 11 adults with ALL had responses meeting protocol definitions, although peripheral blast counts tended to decrease with therapy in all groups. Mucosal toxicity was minimal, even with limited use of leucovorin rescue. Complete bioavailability of aminopterin was confirmed, with a mean area under the curve of 0.52 ± 0.03 µmol hour/L after oral dosing. No relationship between aminopterin pharmacokinetics and response was seen. In vitro, aminopterin showed more consistent metabolism by leukemic blasts to polyglutamates than methotrexate. Lineage-specific differences in the pattern of intracellular antifolylpolyglutamates were observed.

Conclusions: Weekly oral aminopterin has significant activity among children with refractory ALL. With greater cellular accumulation and metabolism, more reliable bioavailability than methotrexate, and tolerable toxicity at this dose and schedule, aminopterin deserves further study as a potent alternative to methotrexate.

This article has been cited by other articles:

				S. Malempati, H. S. Nicholson, J. M. Reid, S. M. Blaney, A. M. Ingle, M. Krailo, L. C. Stork, A. S. Melemed, R. McGovern, S. Safgren, et al. Phase I Trial and Pharmacokinetic Study of Pemetrexed in Children With Refractory Solid Tumors: The Children's Oncology Group J. Clin. Oncol., April 20, 2007; 25(12): 1505 - 1511. [Abstract] [Full Text] [PDF]

				P. D. Cole, R. A. Drachtman, A. K. Smith, M. Masterson, J. Glod, and B. A. Kamen Phase IIB Trial of Aminopterin in Multiagent Therapy for Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) at High Risk of Relapse. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 1860 - 1860. [Abstract] [PDF]